HAVCR2 and chronic myelomonocytic leukemia: There is an ongoing phase III trial in chronic myelomonocytic leukaemia (CMML) — a rare disease which is related, but distinct, to CML — investigating the efficacy of anti-TIM-3 antibody sabstolimab on overall survival.